On the contrary, TCGA analysis on glioma patient samples shows that high expression of “IL1B-signature” is correlated with high expression of CD133 (a marker of glioma aggressiveness) and associated with poor prognosis [32]. The gene discussed is IL1B; the disease is central nervous system cancer.